Wall Street Zen Upgrades HeartSciences (NASDAQ:HSCS) to Sell

HeartSciences (NASDAQ:HSCS) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.00.

HeartSciences Stock Performance

NASDAQ HSCS opened at $3.39 on Friday. HeartSciences has a fifty-two week low of $1.63 and a fifty-two week high of $4.35. The stock has a 50 day simple moving average of $2.67 and a two-hundred day simple moving average of $2.38. The stock has a market cap of $13.22 million, a P/E ratio of -0.86 and a beta of 1.85.

HeartSciences (NASDAQ:HSCS) last announced its earnings results on Thursday, July 23rd. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22). Sell-side analysts predict that HeartSciences will post -3.04 earnings per share for the current year.

Institutional Investors Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC purchased a new position in HeartSciences Inc. (NASDAQ:HSCS) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences at the end of the most recent reporting period. 17.24% of the stock is currently owned by institutional investors.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.